ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO734

Symptom Recovery after Kidney Transplantation

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Samudio, Ana Maria, University Health Network, Toronto, Ontario, Canada
  • Huang, Crystal, University Health Network, Toronto, Ontario, Canada
  • Groe, Katalin, University Health Network, Toronto, Ontario, Canada
  • Marblestone, Nolan James, University Health Network, Toronto, Ontario, Canada
  • Bartlett, Susan J., McGill University Health Centre, Montreal, Quebec, Canada
  • Howell, Doris, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada
  • Li, Madeline, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada
  • Peipert, John D., Northwestern University Department of Medical Social Sciences, Chicago, Illinois, United States
  • Mucsi, Istvan, University Health Network, Toronto, Ontario, Canada
Background

We report physical and psychological symptom severity and frequency among incident kidney transplant (KT) recipients using Patient Reported Outcomes Measurement Information System (PROMIS) computer adaptive tests (CAT).

Methods

Longitudinal convenience sample of incident (<30 days post-transplant) adult KT recipients, recruited 2021-2024. Participants completed PROMIS CATs at baseline, biweekly for 3 months, and monthly thereafter. PROMIS T are standardized to a mean of 50 and standard deviation (SD) of 10, corresponding to the U.S. general population mean. Scores > 60 or <= 40 indicate moderate-severe symptom severity or function impairment, respectively.

Results

Of 133 participants, 84(63%) were male, 69(58%) were white, 43(35%) had diabetes, and mean(SD) age was 51(15) years. Median (interquartile range) time after transplant at enrolment was 5(3,8) days. At baseline, all domain T-scores were worse than the U.S. population mean and improved significantly by week 12. At week 12, domain T-scores neared the U.S. population mean (Table 1). Mean T-scores at week 24 were similar to week 12, except physical function and pain interference, which showed significant further improvement.

At week 0, the proportion of patients scoring moderate-severe symptom severity or function impairment: fatigue 36%, sleep disturbance 32%, physical function 52%, pain interference 48%, anxiety 36%, and depression 18%. At week 12, the proportion of patients scoring moderate-severe symptom severity or function impairment: fatigue 7%, sleep disturbance 14%, physical function 12%, pain interference 10%, anxiety 11%, and depression 10%. All proportions were significantly lower at week 12 vs week 0, except for depression.

Conclusion

A majority of KT recipients will experience moderate-severe symptom severity or function impairment immediately post-transplant. By week 12, most improve significantly and near levels seen in the U.S. general population. Findings highlight need for systematic symptom screening and support early after kidney transplant.

Funding

  • Private Foundation Support